MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:29Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:H2 receptor antagonists]]
			[[Category:Antisecretory agents]]

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #33

2026-05-23T03:34:50Z

parser-claude batch MedTemplate pre-fill, Top 300 #33

New page

{{MedTemplate
| generic = Famotidine
| brand = Pepcid, Pepcid AC, Pepcid Complete
| structure =
| classes = [[:Category:H2_receptor_antagonists|Histamine H2 receptor antagonist]], [[:Category:Antisecretory_agents|Gastric acid suppressant]]
| uses = <vote slug="gerd-use">GERD</vote>, <vote slug="pud-use">Peptic ulcer disease</vote>, <vote slug="functional-dyspepsia-use">Functional dyspepsia</vote>, <vote slug="stress-ulcer-prophylaxis-use">Stress ulcer prophylaxis (selected ICU patients)</vote>
| starting_dose = 20 mg PO twice daily, or 40 mg at bedtime
| preparations = 10 mg, 20 mg, 40 mg tablets; chewables; 40 mg/5 mL oral suspension; 10 mg/mL IV
| fda_max = 160 mg/d (Zollinger-Ellison); 80 mg/d for routine indications
| pill_id =
| routes = Oral, IV
| onset = 1 hour PO; minutes IV
| duration = 6-12 hours
| halflife = 2.5-3.5 hours; longer in renal impairment<ref name="pepcid-label">FDA Prescribing Information, Pepcid (famotidine), Merck, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/019462s039lbl.pdf</ref>
| bioavailability = 40-45% (oral; not significantly affected by food)<ref name="pepcid-label" />
| pregnancy = Generally considered safe; widely used. Cleared in lactation at low levels.{{citation needed}}
| legal = OTC (10-20 mg) and [[USLegal:Prescription only|Rx-only]] (higher doses) in US
| mechanism = <vote slug="famotidine-mech-claim">Famotidine is a selective competitive antagonist of the histamine H2 receptor on the parietal-cell basolateral membrane, blocking histamine-driven activation of the H+/K+ ATPase and reducing both basal and stimulated gastric acid secretion.</vote> Less potent and shorter-acting than PPIs but with faster on-effect; suitable for on-demand acid suppression. Largely renally cleared; dose-adjust in renal impairment to avoid CNS effects (confusion in elderly)<ref name="pepcid-label" />.
}}

== References ==
<references />

Famotidine - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #33